Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health announced its subsidiary, Napo Pharmaceuticals, submitted an abstract for a clinical study on the effects of crofelemer (Mytesi) on the gut microbiome in HIV/AIDS patients for IDWeek 2021.
The study investigates how crofelemer impacts microbiota in people living with HIV/AIDS undergoing antiretroviral therapy. Mytesi is FDA-approved for treating noninfectious diarrhea in these patients. The findings could provide insights into gut health and inflammation related to HIV.
Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), signed a license agreement with its Italian subsidiary, Napo EU S.p.A., for the development and commercialization of crofelemer and lechlemer in Europe. Napo will receive an upfront payment of $10 million and potential milestone payments. The initial focus is on securing accelerated conditional approval for short bowel syndrome with intestinal failure. Napo EU also plans to explore further indications, contingent on additional payments and funding.
Jaguar Health's subsidiary, Napo Pharmaceuticals, announced the completion of a preclinical toxicology study for lechlemer (NP-300), targeting diarrhea relief from cholera and other infections. Supported by the National Institute of Allergy and Infectious Diseases, this study is crucial for filing an Investigational New Drug (IND) application in early 2022. Lechlemer is derived from Croton lechleri and aims to provide cost-effective treatment, particularly for neglected diseases. The company continues to conduct additional necessary studies for the IND application.
Jaguar Health reported second quarter 2021 results with Mytesi net revenue of approximately $0.4 million, marking an 88% decline from $3.2 million in Q2 2020. Gross revenue for Mytesi fell 22% to $4.9 million compared to $6.3 million in the same quarter last year. The company is shifting to direct sales through specialty pharmacies, which aims to lower distribution costs and enhance patient access. Increased R&D expenses of $3.9 million illustrate ongoing clinical trial commitments. The net loss for the quarter was $14.1 million, worsening from $9.2 million in Q2 2020.
Jaguar Health (NASDAQ:JAGX) has announced a time change for its upcoming investor webcast on August 13, 2021, now scheduled for 8:00 AM Eastern Time.
The company focuses on developing plant-based medications aimed at treating gastrointestinal issues, particularly chronic diarrhea in patients with HIV/AIDS. Their product, Mytesi, is FDA approved for this purpose.
Jaguar will file its Q2 2021 10-Q on the same day as the webcast.
Jaguar Health (NASDAQ:JAGX) announced an investor webcast scheduled for August 13, 2021, at 8:30 AM ET to discuss Q2 financials and company updates. Additionally, in recognition of African Traditional Medicine Day on August 31st, Jaguar is launching an educational awareness contest to honor Indigenous healers. Participants can enter the contest for free, with entries due by 9:00 AM ET on August 31, 2021. The winner will receive a signed painting by Anthony J. Conte. For more details, visit Jaguar's official website.
Jaguar Health (NASDAQ:JAGX) announced the adjournment of its Annual Meeting of Stockholders to September 3, 2021, due to insufficient quorum. Over 75% of votes cast supported proposals 2, 3, 4, and 6. Only an additional 0.84% of eligible stock needs to vote for quorum to be achieved. The company emphasized the importance of shareholder participation, which has been costly and distracting. Stockholders can vote online or through their brokers. No changes were made to the proposals, and the record date remains April 12, 2021.
Jaguar Health (NASDAQ:JAGX) announced an upcoming investor webcast featuring CEO Lisa Conte on July 29, 2021, at 8:30 AM ET. The event aims to provide updates on Jaguar and its subsidiaries, including Napo Pharmaceuticals and Napo EU S.p.A. The recent financing closure by Dragon SPAC for approximately €8.83 million underscores Jaguar's focus on expanding its plant-based gastrointestinal medicines. The company’s Mytesi product, approved by the U.S. FDA, offers symptomatic relief for adults with HIV/AIDS experiencing noninfectious diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) announces an upcoming investor webcast featuring an interview with CEO Lisa Conte on July 29, 2021, at 8:30 AM ET. The session will cover business updates for Jaguar and its subsidiaries, including Napo Pharmaceuticals. Recently, Dragon SPAC S.p.A. completed financing for approximately €8.83 million. Jaguar focuses on developing non-opioid, plant-based medicines for gastrointestinal issues. The FDA-approved product Mytesi® provides symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Jaguar Health (NASDAQ:JAGX) announced the grant of nonstatutory stock options and restricted stock units (RSUs) to two new employees effective July 15, 2021. Each employee received options for up to 8,000 shares at an exercise price of $1.41 per share, vested over three years. Additionally, 4,000 RSUs were granted to each employee, vesting equally over the same period. These grants were approved by the Compensation Committee as an inducement for employment, contingent on continued service with the company.